Literature for teneligliptin (S09.003 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2016
1. Arulmozhiraja,S., Matsuo,N., Ishitsubo,E., Okazaki,S., Shimano,H. and Tokiwa,H.
   Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs - an ab initio fragment molecular orbital study
   PLoS ONE11, e0166275-e0166275. PubMed  Europe PubMed DOI  I
2013
2. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
   A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
   Biochem Biophys Res Commun434, 191-196. PubMed  Europe PubMed DOI  I
2012
3. Fukuda-Tsuru,S., Anabuki,J., Abe,Y., Yoshida,K. and Ishii,S.
   A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
   Eur J Pharmacol696, 194-202. PubMed  Europe PubMed DOI  I
4. Yoshida,T., Akahoshi,F., Sakashita,H., Kitajima,H., Nakamura,M., Sonda,S., Takeuchi,M., Tanaka,Y., Ueda,N., Sekiguchi,S., Ishige,T., Shima,K., Nabeno,M., Abe,Y., Anabuki,J., Soejima,A., Yoshida,K., Takashina,Y., Ishii,S., Kiuchi,S., Fukuda,S., Tsutsumiuchi,R., Kosaka,K., Murozono,T., Nakamaru,Y., Utsumi,H., Masutomi,N., Kishida,H., Miyaguchi,I. and Hayashi,Y.
   Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
   Bioorg Med Chem20, 5705-5719. PubMed  Europe PubMed DOI  I